RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

Details about genomic landscapes of AML and endometrial cancer revealed

Two studies from The Cancer Genome Atlas program reveal details about the genomic landscapes of acute myeloid leukemia and endometrial cancer.

2 May 2013

New hope for patients with myotonic dystrophy

There's hope for patients with myotonic dystrophy. A new small molecule developed by researchers at the University of Illinois has been shown to break up the protein-RNA clusters that cause the disease in living human cells, an important first step toward developing a pharmaceutical treatment for the as-yet untreatable disease.

2 May 2013

New study sheds light on DEAD-box proteins

Proteins, the workhorses of the body, can have more than one function, but they often need to be very specific in their action or they create cellular havoc, possibly leading to disease.

30 Apr 2013

Analysis identifies 37 RNA molecules that might predict survival in breast cancer patients

A Big Data analysis that integrates three large sets of genomic data available through The Cancer Genome Atlas has identified 37 RNA molecules that might predict survival in patients with the most common form of breast cancer.

30 Apr 2013

Novel strategy for characterizing RNAs transported from nerve cell to synapse

Despite decades of research, relatively little is known about the identity of RNA molecules that are transported as part of the molecular process underpinning learning and memory.

26 Apr 2013

Study: Blocking certain enzymes in cell may prevent cancer cell division and growth

Blocking certain enzymes in the cell may prevent cancer cell division and growth, according to new findings from researchers at the Graduate School of Biomedical Sciences at the Icahn School of Medicine at Mount Sinai.

26 Apr 2013

Research on miRNAs offers new therapeutic potential to fight diseases

RNA molecules, made from DNA, are best known for their role in protein production. MicroRNAs (miRNAs), however, are short (~22) nucleotide RNA sequences found in plants and animals that do not encode proteins but act in gene regulation and, in the process, impact almost all biological processes - from development to physiology to stress response.

26 Apr 2013

Studies demonstrate encouraging results for new direct-acting antiviral agents

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2013 demonstrate encouraging results in the use of new direct-acting antiviral agents (DAAs) for the treatment of hepatitis C.

25 Apr 2013

Cell sorting device improves detection of circulating tumor cells

An automated cell sorting device developed in the USA may allow circulating tumor cells to be detected with greater accuracy than by current methods, say researchers.

25 Apr 2013

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex Pharmaceuticals Incorporated today announced new data from an interim analysis of the exploratory global Phase 3b CONCISE study evaluating the potential to shorten total treatment with telaprevir combination therapy to 12 weeks in certain people with genotype 1 chronic hepatitis C virus infection who have the IL28B CC genotype.

25 Apr 2013

Researchers decode toggle switch that can stimulate fat burning

For a long time, scientists have dreamt of converting undesirable white fat cells into brown fat cells and thus simply have excess pounds melt away. Researchers at the University of Bonn have now gotten a step closer to this goal: They decoded a "toggle switch" in mice which can significantly stimulate fat burning.

24 Apr 2013

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals for the treatment of hepatitis C virus infection, continue to demonstrate high sustained viral response rates against genotype 1 HCV, across patient types.

24 Apr 2013

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.

24 Apr 2013

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Janssen R&D Ireland today announced primary efficacy and safety results from two global Phase 3 studies demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naive genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin.

24 Apr 2013

Isis Pharmaceuticals starts ISIS-SMNRx Phase 2 study in infants with SMA

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy. SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness and is the most common genetic cause of infant mortality.

24 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Medivir AB today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 hepatitis C patients.

23 Apr 2013

Experimental drug can reduce breast-cancer aggressiveness, restore drug-sensitivity

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggests that an unusual experimental drug can reduce breast-cancer aggressiveness, reverse resistance to the drug fulvestrant and perhaps improve the effectiveness of other breast-cancer drugs.

23 Apr 2013

GeneCapture developing new device with one-hour pathogen testing capabilities

A company hatched as a partnership between The University of Alabama in Huntsville and chemical engineering professor Dr. Krishnan Chittur is in the design phase for a device that can provide physicians one-hour pathogen testing capabilities.

23 Apr 2013

University of Utah researchers develop novel technique to identify RNA cytosine methyltransferases

Researchers from Huntsman Cancer Institute at the University of Utah have developed a novel and powerful technique to identify the targets for a group of enzymes called RNA cytosine methyltransferases in human RNA.

23 Apr 2013

RNA News and Research

Further Reading

Details about genomic landscapes of AML and endometrial cancer revealed

New hope for patients with myotonic dystrophy

New study sheds light on DEAD-box proteins

Analysis identifies 37 RNA molecules that might predict survival in breast cancer patients

Novel strategy for characterizing RNAs transported from nerve cell to synapse

Study: Blocking certain enzymes in cell may prevent cancer cell division and growth

Research on miRNAs offers new therapeutic potential to fight diseases

Studies demonstrate encouraging results for new direct-acting antiviral agents

Cell sorting device improves detection of circulating tumor cells

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Researchers decode toggle switch that can stimulate fat burning

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Isis Pharmaceuticals starts ISIS-SMNRx Phase 2 study in infants with SMA

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Experimental drug can reduce breast-cancer aggressiveness, restore drug-sensitivity

GeneCapture developing new device with one-hour pathogen testing capabilities

University of Utah researchers develop novel technique to identify RNA cytosine methyltransferases

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News